Conditionally immortalized TM cell and RGC lines from Animal Model
Conditionally immortalized TM cell and RGC lines from Animal Model
批准号:
8636379
负责人:
Abbot Frederick Clark
金额:
$14.5万
依托单位国家:
美国
项目类别:
财政年份:
2014
资助国家:
美国
项目状态:
已结题
起止时间:
2014-02-01 至 2016-01-31
关键词:
AddressAdultAffectAnatomyAnimal ModelAnteriorAnterior eyeball segment structureAqueous HumorBiologyBlindnessCell CountCell Culture TechniquesCell LineCellsCellular biologyCharacteristicsDataDiseaseEyeEye diseasesGenetic EngineeringGlaucomaGoalsGrantHigh temperature of physical objectIndividualInterferonsLarge T AntigenLearningMagnetismMajor Histocompatibility ComplexMethodsMicrospheresMolecularMolecular BiologyMorphologyMouse StrainsMusMuscle FibersNeonatalNeurosciences ResearchOptic NervePathogenesisPathway interactionsPhenotypePhotoreceptorsPhysiologic Intraocular PressurePopulationPrimary Cell CulturesPrimatesProliferatingPropertyPublicationsRattusResearchResearch PersonnelResistanceResourcesRetinaRetinalRetinal Ganglion CellsRodentSiteStructure of sinus venosus of scleraTemperatureTestingTherapeutic AgentsTissuesTrabecular meshwork structureVisionVisual impairmentWorkanterior chambercell typecold temperaturecollecting tubule structureimmortalized cellinnovationmagnetic fieldmouse modelnovelnovel therapeuticspromoterpublic health relevanceresearch studytool
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Abstract
Glaucoma is a leading cause of irreversible vision loss and blindness in the world. Two major sites of
glaucoma damage are the trabecular meshwork (TM), which leads to elevated intraocular pressure, and retinal
ganglion cells (RGCs) that progressively die in glaucoma, leading to the loss of vision associated with this
disease. A great deal has been learned about the cell and molecular biology of glaucoma through research on
cultured TM cells and RGCs. However, there are significant limitations with current TM cell and RGC cultures.
TM cells grow relatively slowly and rapidly senesce, limiting studies to relatively small cell numbers of early cell
passages. RGCs are terminally differentiated, and therefore, primary RGCs must be prepared from neonatal
rodent eyes for each experiment conducted. Although immortalized cell lines have been generated, these cells
continuously proliferate in culture and have lost other phenotypic characteristics of primary TM cells and
RGCs. There is a definite need for new TM cell and RGC lines that can be easily propagated and still
retain the phenotypic characteristics of primary cell cultures. The ImmortoMouse was developed as a
unique resource to generate conditionally immortalized cells from a wide variety of tissues that will
continuously proliferate when the cells are cultured at permissive temperatures, but regain their normal
phenotypes when grown at non-permissive temperatures. Our hypothesis is that conditionally immortalized
mouse RGC and TM cell lines from the ImmortoMouse can be isolated, which will have the characteristics of
primary TM cells and RGCs when grown under non-permissive conditions. The following Specific Aims will
address this hypothesis. (SA#1) We will develop and characterize conditionally immortalized mouse TM
cell lines that will rapidly proliferate under permissive conditions (culture at 33oC with ¿IFN) and will have
characteristics of primary TM cells when grown under non-permissive conditions (culture at 39oC without ¿IFN).
(SA#2) We will develop and characterize conditionally immortalized mouse RGC lines that will rapidly
proliferate under permissive conditions and will have characteristics of primary RGCs when grown under non-
permissive conditions. This project is very innovative in several ways. (A) We will isolate and characterize the
first conditionally immortalized TM and RGC cell lines. (B) We also have developed a novel method using
phagocytized magnetic microspheres to purify mouse TM cells. These lines will be made available to a wide
variety of vision researchers to: (a) better understand TM and RGC biology, (b) discover and characterize
new pathogenic pathways, and (c) test potential new therapeutic agents.
!
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Glucocorticoids, ocular hypertension and glaucoma
-
批准号:10468972
-
项目类别:
-
资助金额:$54.04万
-
财政年份:2020
-
负责人:Abbot Frederick Clark
-
依托单位:
Glucocorticoids, ocular hypertension and glaucoma
-
批准号:10675041
-
项目类别:
-
资助金额:$55.71万
-
财政年份:2020
-
负责人:Abbot Frederick Clark
-
依托单位:
Glucocorticoids, ocular hypertension and glaucoma
-
批准号:10056541
-
项目类别:
-
资助金额:$55.9万
-
财政年份:2020
-
负责人:Abbot Frederick Clark
-
依托单位:
Glucocorticoids, ocular hypertension and glaucoma
-
批准号:10261587
-
项目类别:
-
资助金额:$54.04万
-
财政年份:2020
-
负责人:Abbot Frederick Clark
-
依托单位:
Novel Genome Editing for the Treatment of Glaucoma
-
批准号:10613463
-
项目类别:
-
资助金额:$47.34万
-
财政年份:2019
-
负责人:Abbot Frederick Clark
-
依托单位:
Administrative Supplement for Research on Vitamin B3 Dietary Supplements for Eye Disease
-
批准号:10725441
-
项目类别:
-
资助金额:$14.93万
-
财政年份:2019
-
负责人:Abbot Frederick Clark
-
依托单位:
Novel Genome Editing for the Treatment of Glaucoma
-
批准号:9765843
-
项目类别:
-
资助金额:$49.16万
-
财政年份:2019
-
负责人:Abbot Frederick Clark
-
依托单位:
Novel Genome Editing for the Treatment of Glaucoma
-
批准号:10393523
-
项目类别:
-
资助金额:$45.92万
-
财政年份:2019
-
负责人:Abbot Frederick Clark
-
依托单位:
Novel Glaucoma Treatment Using Genome Editing
-
批准号:9254557
-
项目类别:
-
资助金额:$50.84万
-
财政年份:2014
-
负责人:Abbot Frederick Clark
-
依托单位:
Novel Glaucoma Treatment Using Genome Editing
-
批准号:9039605
-
项目类别:
-
资助金额:$50.84万
-
财政年份:2014
-
负责人:Abbot Frederick Clark
-
依托单位:
Conditionally immortalized TM cell and RGC lines from Animal Model
-
批准号:8797099
-
项目类别:
-
资助金额:$17.76万
-
财政年份:2014
-
负责人:Abbot Frederick Clark
-
依托单位:
A New Model of Human Primary Open-Angle Glaucoma
-
批准号:7773778
-
项目类别:
-
资助金额:$21.75万
-
财政年份:2010
-
负责人:Abbot Frederick Clark
-
依托单位:
A New Model of Human Primary Open-Angle Glaucoma
-
批准号:8018064
-
项目类别:
-
资助金额:$17.4万
-
财政年份:2010
-
负责人:Abbot Frederick Clark
-
依托单位:
Glucocorticoids, ocular hypertension, and glaucoma
-
批准号:8236475
-
项目类别:
-
资助金额:$38.27万
-
财政年份:2005
-
负责人:Abbot Frederick Clark
-
依托单位:
Glucocorticoids, ocular hypertension, and glaucoma
-
批准号:8618903
-
项目类别:
-
资助金额:$36.92万
-
财政年份:2005
-
负责人:Abbot Frederick Clark
-
依托单位:
Glucocorticoids, ocular hypertension, and glaucoma
-
批准号:8425036
-
项目类别:
-
资助金额:$35.79万
-
财政年份:2005
-
负责人:Abbot Frederick Clark
-
依托单位:
海外基金